MICROCURES - Key Persons

Dr. Nivaggioli served as CEO of Avicena, a company focused on neurodegenerative diseases, such as ALS, Huntington and Parkinson, where she brought all programs from Phase I to III, with grants from NIH of over $80M and additional funding from VCs. These programs were all licensed at Phase III stage to Marathon Pharma. Dr. Nivaggioli also served as CEO of Peninsula Skincare labs, a dermaceutical company and QuRetino, a pre-clinical stage dermatology company, as well as holding senior level positions at Gillette Corp R&D. She is currently a managing partner at CN Partners, a consulting firm for dermatology companies, where she is focused on launching a new topical lidocaine product for cosmetic dermatologists using a novel transdermal delivery technology.

Job Titles:

• Chairman
• CHAIRMAN of the Board of Directors
• Chief Executive Officer
• Co - Founder
• Investor
• Member of the Senior Leadership Team
• General Partner at the Venture Capital Firm Mohr Davidow Ventures

Derek Proudian is a Silicon Valley venture investor, start-up CEO, and entrepreneur. He has served as the CEO of six venture-capital backed companies. Mr. Proudian has worked as a general partner at the venture capital firm Mohr Davidow Ventures (MDV), a venture partner at Morgan Stanley Ventures, and as an R&D manager at Hewlett-Packard Labs. As a general partner at MDV he was part of a team credited with delivering $3.5 billion in returns to limited partners from an initial $225 million investment. As a founding board member, Mr. Proudian has helped shepherd a number of companies to highly successful exits on behalf of founders and shareholders, including: mSpot, which was sold to Samsung in 2012; Daintree Networks, which was sold to General Electric in 2016; SquareTrade, which was sold to Allstate in January 2017; and Newtrax Technologies, which was sold to Sandvik AB in June 2019. He received a BS in Cognitive Science, a BA in Creative Writing, an MS in Computer Science, and an MBA from Stanford University.

Job Titles:

• Chief Science Officer
• Co - Founder
• Member of the Senior Leadership Team
• MicroCures' Founder and Chief Scientific Officer
• Professor of Physiology

Dr. David Sharp is Professor of Physiology and Biophysics, Ophthalmology and Visual Sciences, and Neuroscience at the Albert Einstein College of Medicine in New York City. He is recognized as one of the world's foremost experts on microtubules and cell movement, with numerous publications in prestigious journals including Cell, Nature, Nature Cell Biology, and Proceeding of the National Academy of Sciences. His career-long research focus has been on the roles and regulation of the microtubule cytoskeleton in cell migration, division, and morphogenesis, as well as harnessing these mechanisms for tissue repair. He has co-authored over 60 papers on this topic to date and has received multiple research grants from federal and state government agencies and private foundations. Dr. Sharp's research has led to the identification of enzymes that can be targeted in vivo to predictably alter cellular motility in a variety of clinical contexts related to tissue repair and regeneration, for which he has been issued seven U.S. patents. He is now leading the therapeutic translation of these findings for MicroCures. Dr. Sharp has been the recipient of numerous research awards from the National Institutes of Health and the Department of Defense. He also has received the LaDonne H. Schulman Excellence in Teaching Award and is a scholar of the Leukemia and Lymphoma Society. Dr. Sharp holds a bachelor's degree in psychology and a Ph.D. in neuroscience at the University of Wisconsin.

Dr. Felice Shieh is a business and corporate development professional with over 16 years of experience on both the sell side and buy side in healthcare across technology platforms, therapeutics, and diagnostics. She has led the diligence and execution of 12+ global and regional partnerships at over billion dollar valuations. In addition to licensing, Dr. Shieh has led early stage fundraising and company formation efforts for four organizations. She brings a wide breadth of leadership and cross-functional expertise from Onyx/Amgen, Medivation/Pfizer, Alexandria Ventures, and BeiGene. She holds a PhD in Chemical Engineering from the University of Texas in Austin and an MBA from Saint Joseph's University.

Dr. Hanson has 27 years of experience as a scientific advisor, physician, researcher, and author.He served for 17 years as a U.S. Air Force (USAF) Senior Flight Surgeon. He also served as the Division Chief for Science & Technology and the Chief of Operational Biotechnology and Genomics at the USAF Surgeon General's office, where he was responsible for technology assessments,research oversight and funding prioritization. In this position, he was designated the USAF programmatics lead for the Congressionally Directed Medical Research Programs (CDMRP). Dr.Hanson has been awarded over $68 million in research grants as a principal investigator. He has written four books and two dozen peer-reviewed articles, holds eight patents, and is the founder of five companies. He is an affiliate Associate Professor and Graduate Faculty Advisor at Oregon Health & Science University in the Department of Medical Informatics and Clinical Epidemiology, and he also is an adjunct Associate Professor at the University of Nevada Las Vegas in the Department of Health Physics and Diagnostic Sciences. Dr. Hanson earned his M.D.from the Uniformed Services University of the Health Sciences, Bethesda, Maryland, and holds a Masters of Public Health (MPH) degree in epidemiology with a genetics concentration from Johns Hopkins University.

Job Titles:

• Professor of Plastic & Reconstructive Surgery

Dr. Gurtner is a Professor of Plastic & Reconstructive Surgery, Vice Chairman of Surgery for Innovation, Executive Director of Stanford Advanced Wound Care Center, and President of Wound Healing Society. He has an extensive publication record.

Dr. Küpper has more than 30 years of experience in biotechnology, including activities ranging from research to R&D management to technology assessment and acquisition. He joined Global Life Science Ventures in 1999 as a managing director of GLSI's advisory company, based in Munich, Germany. His career in biotech began in 1980 at Biogen, one of the first biotech companies, at its European headquarters in Geneva. In 1985, he joined Behringwerke AG to establish and head their molecular biology department. Later, Dr. Küpper became head of R&D and member of the board of the company's immunology/oncology business unit. His most recent non-executive board seats have included Pieris AG (Freising, Germany, chairman); Santaris A/S (Copenhagen, Denmark); Action Pharma A/S (Copenhagen, Denmark); IMI, Intelligent Medical Implants AG (Zug, Switzerland); and Intercell AG (Vienna, Austria). Dr. Küpper received his Ph.D. from the University of Heidelberg in 1974 and spent two years as a post-doctoral fellow at MIT in Boston with Nobel Laureate Har Gobind Khorana.

Job Titles:

• Financial Services Industry Strategist

An experienced financial services industry strategist and entrepreneur, Mr. Hanson has worked as a senior advisor to a broad range of financial/professional service companies, boards, founders, investors and leadership teams spanning investment banking and capital markets, asset management, private equity and credit, real estate, insurance, healthcare, financial technology, venture capital and other service-oriented sectors. Defining, achieving, and re-inventing "success" across business, market, and organizational life cycles is Hanson Advisors' key focus with client-partners -particularly private partnerships and companies in transition. Mr. Hanson also was a founding member of a successful institutional money management business, Milestone Capital Management, after beginning his career on Wall Street with Goldman, Sachs & Co. An active early and growth stage investor, Mr. Hanson serves on the boards and advisory boards of a number of healthcare, service and technology-enabled companies. He holds a BA from Oberlin College and an MBA from Johnson Graduate School of Management at Cornell University.

Dr. Kralstein attended Albert Einstein College of Medicine, New York Medical College, and Columbia University. He is a global pharmaceutical executive and physician with extensive and diverse experience leading, creating, and delivering product development strategies across drug phases and regulatory approval processes. He holds multiple leadership, drug development, and medical positions with Novartis Pharmaceuticals and Procter & Gamble Pharmaceuticals.

Dr. Davies is a biochemist who for the past 20 years has researched the underlying molecular mechanisms of urogenital disease with the goal of identifying and developing new strategies for their treatment. He currently serves as Professor of Urology, Physiology and Biophysics and Director of the Basic Urology Research Laboratories at Albert Einstein College of Medicine. Dr. Davies has authored more than 60 peer reviewed publications and is director of a recently established NIH Center to apply nanotechnology to advance urologic research.

Melanie attended University of Pittsburgh/MIT and is currently a 3M & Wound Healing Foundation Fellow and Instructor at Stanford. She is a strategy and competitive intelligence professional for various biotech and pharmaceutical companies, an engagement Manager at Prescient Healthcare Group; and previously a Product Manager at Orca Bio.

Job Titles:

• Professor

Dr. Singer is Professor Anatomy and Structural Biology (co-chair), Cell Biology, and Neuroscience at the Albert Einstein College of Medicine, as well as co-director of the Gruss Lipper Biophotonics Center and the Integrated Imaging Program. He also is a senior fellow at the Janelia Research Campus of the Howard Hughes Medical Institute. Dr. Singer's research focuses on the cell biology of RNA, including the translation of information encoded in DNA into proteins. His lab developed a patented technique for detecting RNA in preserved cells and has been instrumental in developing rapid and sensitive microscopy for studying single molecules of RNA in living cells, as well as devising methods to track them through their life cycle. This technology has significant implications for understanding the role of RNA in disease processes such as cancer metastasis and in developmental processes leading to intellectual disability. Dr. Singer holds 12 patents on his work. Dr. Singer has received numerous awards for excellence in scholarship and research. He serves on a wide range of editorial boards and scientific advisory boards, and is also a member of many different distinguished professional societies, including induction into the Academy of Arts and Sciences (2009) and the National Academy of Sciences (2013).Hereceived an undergraduate degree in physical chemistry fromOberlin College and a Ph.D. in developmental biology fromBrandeis University. He did postdoctoral work inmolecular biologyat MITand at theWeizmann Institute of Science in Rehovot, Israel.

Job Titles:

• CHIEF MEDICAL OFFICER
• Chairman and Professor, Department of Ophthalmology & Visual Sciences at the Albert Einstein College of Medicine
• Specialist

Roy S. Chuck, MD, PhD, is Chairman and Professor, Department of Ophthalmology & Visual Sciences at the Albert Einstein College of Medicine and the Montefiore Health System. He currently holds the Henkind Chair at Einstein-Montefiore, and previously served as the Tom Clancy Professor and Director of Refractive Surgery at the Wilmer Eye Institute of Johns Hopkins University and professor of ophthalmology and bioengineering at the University of California Irvine. Dr. Chuck's clinical focus is in cornea and external diseases as well as refractive surgery. After earning his Bachelor of Science in engineering at University of California, Berkeley, in 1986, Dr. Chuck attended Columbia University, earning his Doctor of Medicine and Doctor of Philosophy in 1993. He started his postdoctoral training at St. Mary's Health Center, completing a yearlong internship in internal medicine in 1994. From then until 1998, he pursued a residency in ophthalmology at Washington University and Barnes Hospital, acting as faculty chief resident in his final year. In 1999, he completed a yearlong fellowship in cornea and refractive surgery at the Doheny Eye Institute, University of Southern California. Dr. Chuck's research follows his clinical focus. His research has been published in numerous peer-reviewed journals as well as shared through many patents, abstracts, book chapters and podium and poster presentations. He has been an editor and served on the editorial boards of many publications including the Lasers in Surgery and Medicine, Journal of Refractive Surgery, Current Opinion in Ophthalmology, BMC Ophthalmology, AAO Preferred Practice Patterns and Cochrane Reviews. He currently serves as the Editor-in-Chief of the major journal ARVO Translational Vision Science and Technology and is a member of the NIH National Eye Institute Council of Editors. Dr. Chuck has been recognized for many achievements and contributions to his discipline and the community. Among his many accolades include being awarded the American Academy of Ophthalmology Senior Achievement and Secretariat Awards, Fight For Sight Physician-Scientist of the Year, the Lions Club International Melvin Jones Fellow/Humanitarian Award and the NYC Chinatown Honor Award for Community Service. He is board certified and is a member of many local, national and international professional societies including the American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology, the International Society for Refractive Surgery, the American Society for Laser Medicine and Surgery, and the Manhattan Ophthalmological Society. He currently serves as Secretary for Quality of Care for the United States' American Academy of Ophthalmology. Dr. Chuck is a cornea specialist and board certified ophthalmologist. He has expertise in the field of laser techniques for refractive eye problems and has published, patented and lectured extensively throughout his career. Dr. Chuck also has strong research interests in dry eye, ocular surface stem cells and corneal transplantation. At present, he is Professor of Ophthalmology and Genetics and the longstanding Chairman of the Department of Ophthalmology and Visual Sciences at the Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, one of the largest eye care centers in the U.S.